HHS Drug Pricing Proposals: Some Things Are Off The Table
Executive Summary
The US Centers for Medicare and Medicaid Services is proposing an interesting package of innovative pricing policy changes, but some of the topics not included might be as important as the ideas that are.
You may also be interested in...
Could Drug Shortages Unlock Changes To Medicare Part B Payment?
The push to change the ‘ASP+6%’ reimbursement for physician-administered drugs in the US Medicare program is almost as old as the formula itself. Will the current drug shortage crisis provide a trigger to make changes at last?
Medicare Part D Redesign Will Sharpen Policy Focus On Protected Classes
Manufacturers worry that the redesign will prompt tighter controls in the protected classes, while some research indicates plans are already using all the tools at their disposal to manage some key classes, such as cancer drugs, suggesting they may need to be able to do more.
Medicare Will Test Payment Model For Accelerated Approvals To ‘Expedite’ Confirmatory Trials
The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.